All Eisai articles
-
OpinionFrom one sinking ship to another?
Biogen abandoning Alzheimer’s antibody aducanumab is unusual, but hardly surprising, says Derek Lowe
-
BusinessAntibodies face Alzheimer’s reality
Companies are convincing regulators, but will doctors use them, and will providers pay for them?
-
BusinessBiogen to cut 1000 more jobs by 2025
Biotech giant has also agreed to buy Reata Pharmaceuticals for $7.3 billion
-
BusinessSecond Alzheimer’s antibody approved in the US
Biogen–Eisai’s lecanemab can slow disease progression a little, but at significant cost and risk of side effects
-
BusinessAlzheimer’s antibody engenders anticipation
Tantalising press-released data on Biogen and Eisai’s lecanemab prompt questions without firm answers
-
BusinessBMS and Eisai agree antibody-drug conjugate commercialisation deal
Companies will jointly develop cancer treatment, with BMS paying up to $3 billion for shared rights
-
Business
Japanese pharma opens compound vaults
Molecule libraries to be screened for neglected diseases
-
News
FDA green lights new obesity drug
Agency approval for prescription only obesity drug is first for 13 years